Randomized Phase II Trial of Capecitabine and Lapatinib with or without IMC-A12 (Cituxumumab) in Patients with HER2-Positive Advanced Breast Cancer Previously Treated with Trastuzumab and Chemotherapy: NCCTG N0733 (Alliance)

Purpose To compare efficacy and safety of capecitabine and lapatinib with or without IMC-A12 (cituxumumab) in patients with HER2-positive metastatic breast cancer (MBC) previously treated with trastuzumab. Patients and methods Following an initial safety run-in cohort, patients were randomized 1:2 t...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Breast cancer research and treatment 2021-07, Vol.188 (2), p.477-487
Hauptverfasser:	Haddad, Tufia C., He, Jun, O’Sullivan, Ciara C., Chen, Beiyun, Northfelt, Donald, Dueck, Amylou C., Ballman, Karla V., Tenner, Kathleen S., Linden, Hannah, Sparano, Joseph A., Hopkins, Judith O., De Silva, Chamath, Perez, Edith A., Haluska, Paul, Goetz, Matthew P.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adverse events Antibodies, Monoclonal, Humanized Antineoplastic Combined Chemotherapy Protocols - adverse effects Breast cancer Breast Neoplasms - drug therapy Cancer research Capecitabine - therapeutic use Chemotherapy Clinical Trial Diarrhea Disease-Free Survival ErbB-2 protein Female Humans Inhibitor drugs Lapatinib - therapeutic use Medicine Medicine & Public Health Metastases Monoclonal antibodies Oncology Patients Quality of Life Quinazolines - adverse effects Receptor, ErbB-2 - genetics Safety Survival Targeted cancer therapy Trastuzumab Trastuzumab - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!